Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.54 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10578047 | 0.86 | ADORA1 (0.52) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11409612 | 0.85 | ADORA2B (0.70) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11409631 | 0.85 | ADORA2B (0.70) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL7321542 | 0.84 | AHCY (0.62) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11416011 | 0.84 | ADORA2B (0.69) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11415994 | 0.84 | ADORA2B (0.69) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11518501 | 0.83 | ADORA2B (0.70) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL14696726 | 0.83 | PRKACA (0.61) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL11703639 | 0.82 | PRKACA (0.61) | ADORA3ADORA2BADORA2AADORA1HSP90B1 | |
| SCHEMBL14696395 | 0.81 | PRKACA (0.65) | ADORA3ADORA2BADORA2AADORA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0222330-A2 | N6-Substituted-5'-oxidized adenosine analogs | WARNER-LAMBERT COMPANY (US) | 1987-05-20 | — | — | EP | claimed |
| US-20050118262-A1 | Controlled release formulation | ADERIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005025545-A2 | PHARMACEUTICAL FORMULATION FOR CONTROLLED RELEASE OF SELODENOSON | ADERIS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050009776-A1 | Method of treating atrial fibrillation or atrial flutter | ADERIS PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040242531-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242930-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADERIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6784165-B1 | ADENOSINE A1 RECEPTOR AGONISTS | ADERIS PHARMACEUTICALS, INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1239864-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6 -SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | Aderis Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001037845-A1 | TREATMENT OF HEART RHYTHM DISTURBANCES WITH N6-SUBSTITUTED-5'-(N-SUBSTITUTED) CARBOXAMIDOADENOSINES | ADERIS PHARMACEUTICALS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009776-A1 | Method of treating atrial fibrillation or atrial flutter | ADORA2A, HCN3, SCN9A | ADORA3 7/4885ADORA2B 27/4885ADORA2A 1/4885 |
| US-20040242930-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADRA1D, ADORA1, ADRA2C | ADORA3 5/4885ADORA2B 14/4885ADORA2A 6/4885 |
| US-20050118262-A1 | Controlled release formulation | TNNC1, ATP2A1, RYR2 | ADORA3 88/4885ADORA2B 75/4885ADORA2A 73/4885 |
| US-20040242531-A1 | Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines | ADRA1D, ADORA1, ADRA2C | ADORA3 5/4885ADORA2B 14/4885ADORA2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.